CTOs on the Move

Neurelis

www.neurelis.com

 
Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company devoted to developing treatment options for epilepsy, while also investigating new treatment options for the unmet needs of central nervous system (CNS) disorders.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.neurelis.com
  • 11682 El Camino Real Suite 255
    San Diego, CA USA 92130
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Neurelis raised $114M on 03/10/2021

Similar Companies

BetaTec Hop Products

BetaTec Hop Products is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Osmind

Osmind is building the digital infrastructure for the next era of mental health. Osmind EHR is the #1 software for treatment-resistant mental health practices such as those in psychiatry, ketamine, psychedelic medicine, and neuromodulation.

A and J Consulting Engineering Services, PC

A and J Consulting Engineering Services, PC is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HelpAround

Your patient journey.Made even better. We connect specialty pharma to its vendors within one easy gateway. No app needed. See it for yourself All your vendors. All in one place. ic_24px/insurance Capture missing info No more chasing down incomplete pap...

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.